Uridine for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Uridine for Health & Longevity

Created on 09/16/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A normal blood component the body already makes. Its one firmly established use is emergency rescue from chemotherapy poisoning, at doses far above supplement levels. Supplement-scale findings — brief muscle protection during a training break, measurable dry-eye signs — each rest on a single maker-linked trial. Sustained intake disturbed blood sugar and liver fat in rodents; continuous human use is untested. (Full Review)

Protocol

Standard supplement dose
150–300 mg uridine monophosphate daily
Most commonly used range in consumer practice; Examine places typical use at 500–1,000 mg, and controlled trials have used 2,000 mg of plain uridine daily.
Single versus split dosing
Splitting doses above 300 mg into two
The short half-life favours splitting, though no trial has compared schedules; trial regimens ranged from a single 2,000 mg dose to 500 mg twice daily.
Best time of day
Morning, with a meal
With the fat-containing meal if docosahexaenoic acid is taken alongside; morning dosing avoids overlap with the overnight fasting rise in endogenous uridine.
Time to effect
Muscle thickness
1 week
Preservation of upper-arm muscle thickness during a training layoff; no difference at two weeks.
Dry eye signs
3 months
Corneal staining and tear production separated from placebo at three months and not at one month; symptom scores did not.
Mood scores
2–4 weeks
An absence of any perceived change by 12 weeks leaves no evidence-based reason to continue.

Benefits

Contraindications
  • Fluoropyrimidine chemotherapy (fluorouracil, capecitabine, tegafur), or within 4 weeks of the last dose, outside supervised emergency antidote use
  • Active malignancy treated with any antimetabolite chemotherapy
  • Leflunomide or teriflunomide
  • Gout with a flare in the past 12 months, or serum urate above 6.8 mg/dL
  • Metabolic dysfunction-associated steatotic liver disease, or ALT above twice the upper limit of normal
  • Pregnancy and breastfeeding
  • Children and adolescents outside a supervised trial or an inherited pyrimidine disorder
    •
Key Interactions
  • Other pyrimidine analogues (gemcitabine, cytarabine, capecitabine)
  • Urate-lowering drugs (allopurinol, benzbromarone)
  • Nucleoside transport inhibitors (dipyridamole, ticagrelor)
  • Antiretroviral nucleoside analogues (zidovudine, stavudine)
  • Antacids (calcium carbonate), non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) and loperamide
  • Choline and citicoline supplements
  • Docosahexaenoic acid supplements
  • Alcohol, particularly beer
  • Prolonged fasting and ketogenic patterns
    •

Risk & Side Effects

  • High: Gastrointestinal upset
    •
  • Medium: Reduction in HDL cholesterol
    •
  • Low: Impaired glucose tolerance and hepatic fat accumulation with chronic use; elevated uric acid
    •
  • Speculative: Blunting of fluoropyrimidine chemotherapy efficacy; support for tumour nucleotide and ribose salvage; lowered core body temperature
    •

Monitoring

Marker Target Why
Fasting glucose 75–85 mg/dL Earliest marker of the glucose-intolerance signal seen with chronic dosing
HbA1c (glycated haemoglobin) < 5.4% Integrates glucose over 3 months, matching the timescale of a supplement course
Fasting insulin 2–5 µIU/mL Detects insulin resistance before glucose rises, the mechanism implicated in rodent work
ALT (alanine aminotransferase) < 20 U/L men, < 17 U/L women Tracks the hepatic fat accumulation reported with continuous uridine feeding
Serum urate 3.5–5.5 mg/dL Addresses the correlational uridine–urate relationship before a gout flare
HDL cholesterol > 55 mg/dL men, > 65 mg/dL women The one lipid change a randomised uridine trial recorded
Plasma uridine No established target; tracked as change from the individual's own baseline Confirms the supplement is producing any systemic exposure at all

Cadence: Baseline, repeated at 12 weeks, then every 6–12 months while use continues, with an earlier recheck if gout symptoms, new fatigue or abdominal discomfort appear

Qualitative Assessment

  • Verbal and working memory in daily use — recall of names, ease of holding a thread in conversation
  • Mood stability and the frequency of low days, recorded at a fixed time rather than retrospectively
  • Perceived mental clarity and fatigue in the afternoon
  • Sleep quality and morning alertness
  • Muscle fullness and strength retention across planned training breaks
  • Gastrointestinal comfort — cramping, stool consistency and bloating, the first signal of an excessive dose
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.